Interferon alfa-2b (Intron-A)
General information
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways. Mechanism not fully understood.[1][2][3]
Route: SC, IM, IV, intralesional
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adult T-cell leukemia/lymphoma
- Chronic myelogenous leukemia
- Melanoma
- Multiple myeloma
- Neuroendocrine tumor
- Pancreatic NET
- Renal cell carcinoma
- Systemic mastocytosis
Diseases for which it was used
Patient drug information
- Interferon alfa-2b (Intron-A) patient drug information (Chemocare)[4]
- Interferon alfa-2b (Intron-A) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 6/4/1986: Initial FDA approval
Also known as
Caution, may also contain names for interferon beta, interferon gamma, or interferon alfa-2a.
- Brand names:
Synonyms | |||||||
---|---|---|---|---|---|---|---|
Advaferon | Alfaferone | Berofor | Biogamma | Canferon A | |||
Cytoferon | Egiferon | Feron | Fiblaferon | Frone | |||
Finnferon-Alpha | Heberon Alfa R | Humoferon | IFN Alpha | Imufor | |||
Imukin | INF | Inferax | Infergen | Inmutag | |||
Interfero | Interferon Alfanative | Interferon Human | Interferon Leucocyticum | Interferon Lymphoblastoid | |||
Interferonum Leucocyticum | Laroferon | Multiferon | Namalvin | OIF | |||
Polyferon | Realdiron | Roceron-A | Sumiferon | Wellferon |
References
- Drugs
- Subcutaneous medications
- Intralesional medications
- Intramuscular medications
- Intravenous medications
- Immunotherapeutic
- Interferons
- Adult T-cell leukemia/lymphoma medications
- Chronic myelogenous leukemia medications
- Melanoma medications
- Multiple myeloma medications
- Neuroendocrine tumor medications
- Pancreatic NET medications
- Renal cell carcinoma medications
- Systemic mastocytosis medications
- FDA approved in 1986